Gossamer Bio (NASDAQ:GOSS) Downgraded to “Market Perform” at Raymond James

Raymond James downgraded shares of Gossamer Bio (NASDAQ:GOSS – Get Rating) from an outperform rating to a market perform rating in a report published on Tuesday morning, The Fly reports.

GOSS has been the subject of several other research reports. Sumitomo Mitsui Financial Group cut shares of Gossamer Bio from an outperform rating to a neutral rating and set a $3.00 price target for the company. in a report on Wednesday, December 7th. HC Wainwright lowered their price target on shares of Gossamer Bio from $25.00 to $5.00 and set a buy rating for the company in a report on Thursday, December 8th. The Goldman Sachs Group reduced their price objective on shares of Gossamer Bio from $22.00 to $10.00 and set a buy rating for the company in a research report on Wednesday, December 7th. Evercore ISI reduced their price objective on shares of Gossamer Bio to $7.00 in a research report on Monday, December 12th. Finally, UBS Group reduced their price objective on shares of Gossamer Bio from $19.00 to $8.00 and set a buy rating for the company in a research report on Wednesday, December 7th. One research analyst has rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of Hold and a consensus target price of $10.25.

Gossamer Bio Price Performance

Gossamer Bio stock opened at $1.67 on Tuesday. The company has a debt-to-equity ratio of 3.73, a quick ratio of 5.93 and a current ratio of 5.93. The company has a market capitalization of $157.78 million, a price-to-earnings ratio of -0.58 and a beta of 1.25. The company’s 50 day simple moving average is $2.19 and its 200-day simple moving average is $7.32. Gossamer Bio has a 1 year low of $1.57 and a 1 year high of $15.20.

Institutional Trading of Gossamer Bio

Hedge funds have recently made changes to their positions in the stock. EcoR1 Capital LLC bought a new stake in Gossamer Bio in the third quarter valued at $49,847,000. NEA Management Company LLC purchased a new position in Gossamer Bio in the 3rd quarter worth about $41,540,000. Millennium Management LLC increased its stake in Gossamer Bio by 248.0% in the 4th quarter. Millennium Management LLC now owns 4,625,511 shares of the company’s stock worth $10,037,000 after purchasing an additional 3,296,396 shares in the last quarter. Cormorant Asset Management LP increased its stake in Gossamer Bio by 1,512.2% in the 3rd quarter. Cormorant Asset Management LP now owns 3,198,382 shares of the company’s stock worth $38,317,000 after purchasing an additional 3,000,000 shares in the last quarter. Finally, Weiss Asset Management LP purchased a new position in Gossamer Bio in the 3rd quarter worth about $33,232,000. Institutional investors and hedge funds own 90.18% of the company’s stock.

About Gossamer Bio

(Get Rating)

Gossamer Bio, Inc engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions.